In 2022, the expiration of thousands of drug marketing authorization and delays in drug bidding affected millions of patients nationwide. From research reports on the current state of drug supply, Danson developed summaries of the current situation and explanations of policy bottlenecks to introduce to interested reporters. Nearly 200 communication results conveyed urgent patient needs to healthcare regulatory agencies, members of parliament, and medical experts. All press articles, TV and radio reportages discussed the issues from multidimensional and objective angles, featuring valuable interviews and quotes of vulnerable patients and the HCPs who themselves advocate for the rights to choose good quality drugs in treatment.
Danson also continues its communication efforts on patient access to new medicine, through the development of content related to the Pharmaceutical Law, the Health Insurance Law, and the National Reimbursed Drugs List. By building an effective media relations network and providing valuable information and knowledge to journalists, Danson successfully ensured the quality of healthcare policy content, highlighting the role of innovative pharmaceuticals. At the same time, the reputation and position of innovative pharmaceutical companies were continuously elevated in consulting and supporting the government in improving healthcare policies and developing the pharmaceutical industry.
